• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Methyltransferase Assay Kits
      • Ligase and Synthetase Assay Kits
      • Phosphodiesterase Assay Kits
    • HTS Assays by Target
      • AMPK Assay Kits
      • cGAS Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • TBK1 Assay Kits
    • Recombinant cGAS Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • GTPase Profiling Services
    • OAS1 Assay Services
  • Innate Immunity
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD39 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • OAS1 Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Application Notes
    • Transcreener® Assays – Instrument Compatibility
    • Posters and Presentations
    • Publications
    • Technical Manuals
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

New Publication by the Scientists at BellBrook Labs – Development of a High-Throughput Assay to Identify Inhibitors of ENPP1

by Bellbrook Labs / Thursday, 11 February 2021 / Published in Emerging Targets, HTS Assays, News
Inhibitors of ENPP1 SLAS Discovery

BellBrook scientist Meera Kumar and Robert Lowery were recently published in SLAS Discovery for their work entitled Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. Ectonucleotide pyrophosphatase/phosphodiesterase 1 or ENNP1 has recently become a target for cancer immunotherapy. ENNP1 hydrolyzes nucleotides such as cGAMP and ATP. Cytosolic DNA is a trigger for the innate immune response to cancer. cGAMP is a critical messenger of this immune response, and as such, regulation of ENNP1 could lead to breakthrough treatments.

In the paper, Kumar and Lowery describe the development of an HTS compatible ENPP1 activity assay to discover lead molecules for the enzyme. The technique uses the Transcreener AMP2/GMP2 Assay to measure cGAMP breakdown to AMP and GMP with a 104-fold selectivity. The assay reported a Z’ value of 0.72, demonstrating a robust HTS amiable method.

Also discussed in the article were ENPP1’s preferred substrates.  ATP was selected to be hydrolyzed with greater efficiency when compared to other nucleotides such as ADP, GDP, and ATP. ENNP1 was much more selective for 2’3’ cGAMP with 20-fold selectivity over 2’3’ c-di-GMP and virtually no activity with 3’3’ c-diAMP.

Work done by the scientists at BellBrook Labs will enable further characterization on ENPP1. It also provides an avenue for other researchers to use the assay technique for HTS and lead discovery. By providing a simple single-step mix-and-read method, researchers can interrogate the target with greater efficiency to more quickly discover novel inhibitors and accelerate new treatments to the clinic.

Learn More About the ENPP1 Assay

References

Kumar, M., & Lowery, R. G. Development of a High-Throughput Assay to Identify Inhibitors of ENPP1. SLAS DISCOVERY: Advancing the Science of Drug Discovery, 2472555220982321. https://journals.sagepub.com/doi/abs/10.1177/2472555220982321

Tagged under: ENPP1 Assay, Transcreener AMP/GMP Assay

What you can read next

What’s New at BellBrook Labs? Find Out at SLAS 2017.
CDK12 Activity Assays Find Inhibitors Cancer Treatment
Finding Inhibitors for a Cancer Target: CDK12 Activity Assays Accelerate the Search
BellBrook Labs awarded SBIR Grant for Protein Kinase Assay

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • Researcher Using An ADP Assay

    Accelerating Discovery of Kinase Inhibitors Using an ADP Assay

    An ADP assay can be used to study the activity ...
  • GMP Assay for PDE Inhibitor Discovery

    Using a Universal GMP Assay for PDE Research

    A universal GMP assay to aid in PDE research an...
  • SLAS 2021

    Join Us for SLAS 2021 Virtual Conference

    BellBrook Labs will be exhibiting at SLAS 2021,...
  • New cGAS TR-FRET Assay

    New TR-FRET Readout Now Available with the Transcreener cGAMP cGAS Assay

    Launched in November 2019, the Transcreener cGA...
  • Webinar Graphic

    Previously Recorded Webinar – Streamline cGAS Inhibitor Discovery with the Transcreener® cGAS Assay

    The immune system uses the recognition of forei...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2019 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP